POS0652 INTEROBSERVER RELIABILITY AND SENSITIVITY TO CHANGE OF A COMPOSITE OCULAR INFLAMMATORY ACTIVITY INDEX: UVEDAI

Background Standardized and validated outcome measures of disease activity are lacking in the treatment assessment uveitis, making it difficult to compare efficacy response treatment. In 2014, this working group developed a composite index ocular inflammatory activity, UVEDAI, which includes 7 variables. The was subsequent study conducted 2019. Objectives To determine interobserver reliability demonstrate sensitivity change UVEDAI patients with anterior non-anterior uveitis who undergo pharmacological Methods design is an observational, longitudinal, prospective, multicentre Spanish hospitals. Patients over 18 years age diagnosed active were included. A complete baseline visit performed by two ophthalmologists determined independently without contact between them. Ophthalmologist 1 made new at 4 weeks level uveal using index. analysis calculating Intraclass Correlation Coefficient (ICC), values variables obtained ophthalmologist 2 most inflamed eye visit. Sensitivity assessed from start determining Clinically Relevant Change (CCR) defined as 0.8 points 4-week Results total 111 included, 54.1% male mean time 49.9 years. 36.9% idiopathic 58.6% uveitis. value calculated score recorded 1.9, being 1.2 for 2.8 intermediate/posterior analysis, ICC 0.9, when compared visit, no statistically significant differences found (p-value>0.05), neither sample nor differentiating anatomical location. As change, (p-value=0.00) comparing measured weeks, both overall anatomic location all cases, decreased significantly more than point after Conclusion high different Furthermore, sensitive uveitis/panuveitis. We believe that could be used routine clinical practice studies trials results objectively. Reference [1]Pato-Cour E, Martin-Martinez MA, Castelló A, et al. Development (UVEDAI). Rheumatol Int. 2017;37(4):647-65. Figure Interobserver Reliability Differences 1. Table Sensitive Mean difference weeks. Anatomical Location Anterior Intermediate/ Posterior/Panuvetis Total INDEX baseline.opht.1* 1,2 ± 1,6 2,8 1,8 1,9 wks.opht1* 0,2 0,5 1,5 0,6 1,1 1.04 1.54 1.25 p-value 0.00 *mean standard deviation Disclosure Interests None Declared.